{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:07:23Z","timestamp":1790017643160,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.intimp.2023.111019","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:55:53Z","timestamp":1698108953000},"page":"111019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"PA","title":["Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study"],"prefix":"10.1016","volume":"125","author":[{"given":"Mengya","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4964-2218","authenticated-orcid":false,"given":"Jinzhang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2023.111019_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.intimp.2023.111019_b0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"4","key":"10.1016\/j.intimp.2023.111019_b0015","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","article-title":"Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma","volume":"150","author":"Bruix","year":"2016","journal-title":"Gastroenterology"},{"issue":"10127","key":"10.1016\/j.intimp.2023.111019_b0020","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"issue":"10126","key":"10.1016\/j.intimp.2023.111019_b0025","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.intimp.2023.111019_b0030","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1200\/JCO.2020.38.15_suppl.4506","article-title":"Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II\/III trial","volume":"38","author":"Bi","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2023.111019_b0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/cld.796","article-title":"New drugs effective in the systemic treatment of hepatocellular carcinoma","volume":"14","author":"Montironi","year":"2019","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"7","key":"10.1016\/j.intimp.2023.111019_b0040","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2023.111019_b0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.intimp.2023.111019_b0050","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.intimp.2023.111019_b0055","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"issue":"15_suppl","key":"10.1016\/j.intimp.2023.111019_b0060","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2021.39.15_suppl.4076","article-title":"Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC)","volume":"39","author":"Zhang","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3\u20134","key":"10.1016\/j.intimp.2023.111019_b0065","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1159\/000343875","article-title":"Liver Cancer Study Group of, JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan","volume":"3","author":"Kudo","year":"2014","journal-title":"Liver Cancer"},{"issue":"23","key":"10.1016\/j.intimp.2023.111019_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312880","article-title":"Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma","volume":"22","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2023.111019_b0075","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1)","volume":"40","author":"Lyu","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2023.111019_b0080","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/gutjnl-2017-314138","article-title":"FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin for advanced hepatocellular carcinoma","volume":"67","author":"Lyu","year":"2018","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.intimp.2023.111019_b0085","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and Leucovorin vs Sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.intimp.2023.111019_b0090","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211002720","article-title":"Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma","volume":"13","author":"He","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.intimp.2023.111019_b0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/JHC.S298538","article-title":"Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma","volume":"8","author":"Mei","year":"2021","journal-title":"J. Hepatocell Carcinoma"},{"issue":"8","key":"10.1016\/j.intimp.2023.111019_b0100","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2023.111019_b0105","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3109\/07357909909032859","article-title":"5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy","volume":"17","author":"Iyer","year":"1999","journal-title":"Cancer Invest."},{"issue":"5","key":"10.1016\/j.intimp.2023.111019_b0110","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1200\/JCO.1996.14.5.1495","article-title":"Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors","volume":"14","author":"Clarke","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.111019_b0115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2020.03.032","article-title":"Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: a phase II, single-arm, prospective study","volume":"134","author":"Chen","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"16_suppl","key":"10.1016\/j.intimp.2023.111019_b0120","doi-asserted-by":"crossref","first-page":"e16166","DOI":"10.1200\/JCO.2022.40.16_suppl.e16166","article-title":"Hepatic arterial infusion chemotherapy with oxaliplatin plus raltitrexed versus oxaliplatin plus fluorouracil in intermediate and advanced hepatocellular carcinoma: a retrospective study","volume":"40","author":"Zang","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.intimp.2023.111019_b0125","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1200\/JCO.2022.40.16_suppl.4106","article-title":"Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage c: a prospective, single-arm, phase II trial (TRIPLET study)","volume":"40","author":"Gu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.111019_b0130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","article-title":"Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial","volume":"174","author":"Lai","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2023.111019_b0135","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.111019_b0140","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","article-title":"Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma","volume":"69","author":"Lyu","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2023.111019_b0145","doi-asserted-by":"crossref","first-page":"12683","DOI":"10.2147\/OTT.S286169","article-title":"Safety and efficacy of camrelizumab combined with apatinib for advanced hepatocellular carcinoma with portal vein tumor thrombus: a multicenter retrospective study","volume":"13","author":"Yuan","year":"2020","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.intimp.2023.111019_b0150","article-title":"Lenvatinib plus Camrelizumab vs. Lenvatinib monotherapy as first-line treatment for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923013449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923013449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:04:51Z","timestamp":1761588291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923013449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":30,"alternative-id":["S1567576923013449"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111019","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111019"}}